Tag: Biologics Price Competition and Innovation Act (BPCIA) ⋅ Page 1

Professor Lietzan Speaks on Panel at Supreme Court IP Review

Professor Erika Lietzan recently served as a panelist at the Supreme Court IP Review held at the Chicago-Kent College of Law. She discussed Sandoz, Inc. v. Amgen. Inc., a case decided by the Supreme Court last June. In October 2014, Amgen, a biopharmaceutical company which manufactures Neupogen, an innovative bone marrow stimulant, sued Sandoz, a biopharmaceutical company which manufactures Zarxio,…

Professor Lietzan Files Amicus Brief with U.S. Supreme Court in Patent Case

Professor Lietzan recently filed an amicus brief in the United States Supreme Court, in a closely-watched case involving patent litigation under the Biologics Price Competition and Innovation Act (BPCIA). The appellate court concluded that biosimilar applicants may elect not to comply with the information exchange provisions laid out in the statute, effectively opting out of the statutory premarket patent litigation…